Podcasts about arena pharmaceuticals

Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.  © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026

GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5%! GET ORGANIC COFFEE, MANUKA HONEY AND MUSHROOM TINCTURES HERE: https://madtravnutrition.com/ Use Code "Josh" and save 10%! Support the work of Jaymie Icke & Ickonic! HELP THE WAM LEGAL DEFENSE FUND HERE: https://gogetfunding.com/wam-legal-defense/ BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Josh Sigurdson reports on the announcement by Pfizer and Moderna that they plan to roll out mRNA "catch all" vaccines for any "pandemic influenza" which would refer to absolutely any type of illness. They're replacing all of the already dangerous childhood and influenza vaccines with even more dangerous mRNA versions. This comes as people are beginning to be injected for bird flu with mRNA in places like Finland. It's happening. Not just that, the mRNA vaccines are also being injected into cows and chickens in massive numbers. Many would point out that it's more likely they're using modRNA which surpasses digestion in a human. This means they are already putting this dangerous gene altering substance into humans through the meat supply. The meat supply is already under attack, so adding this to the mix should concern everyone. Pfizer has said previously that so-called "Covid" was just a test run for something much bigger. They're threatening us. Pfizer is also purchasing huge numbers of companies that work in fields that relate to the very injuries their covid mRNA injections cause in the first place. Pfizer has bought Seagan Pharmaceuticals which is a corporation looking at cancer mitigation. Interestingly, cancer has SKYROCKETED since the rollout of the injections. Pfizer has also bought Arena Pharmaceuticals which works in the field of myocarditis and immuno-inflammatory problems. Recently, Pfizer bought Global Blood Therapeutics which works on treating sickle cell disease. Meanwhile, One Health is planning to make doctors only write prescriptions for based on what they deem "beneficial for the planet." They hate you and want you dead. Prepare now! Stay tuned for more from WAM! ORDER QUALITY MEAT TO YOUR DOOR HERE: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 Save 20% and get $15 off your FIRST order! Support your local farms and stay healthy! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ PayPal: ancientwonderstelevision@gmail.com GET AN EXTENDED FREE TRIAL FOR ICKONIC WHEN YOU SIGN UP HERE: https://www.ickonic.com/affiliate/josh10 LION ENERGY: Never Run Out Of Power! PREPARE NOW! https://www.r1kln3trk.com/3PC4ZXC/D2N14D/ STOCK UP ON STOREABLE FOODS HERE: http://wamsurvival.com/ OUR GOGETFUNDING CAMPAIGN: https://gogetfunding.com/help-keep-wam-alive/ Find us on Vigilante TV HERE: https://vigilante.tv/c/world_alternative_media/videos?s=1 See our EPICFUNDME HERE: https://epicfundme.com/251-world-alternative-media JOIN our Telegram Group HERE: https://t.me/worldalternativemedia JOIN US on Rumble Here: https://rumble.com/c/c-312314 FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media We will soon be doing subscriber only content! Follow us on Twitter here: https://twitter.com/WorldAltMedia Help keep independent media alive! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2024

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026

Welcome to the Med Spa Success Strategies Podcast, presented by Ricky Shockley of Med Spa Magic Marketing. On this episode, we're joined by Dr. Brandon Kirsch of Kirsch Dermatology & Med Spa to discuss lessons learned, strategies, and tactics that allowed him to build a highly successful and reputable practice in Naples, FL. Kirsch Dermatology is known for excellence in patient care as evidenced by their incredible online reviews. Dr. Kirsch shares how he went from the "new-in-town" to a highly sought-after provider with the help of online marketing and an emphasis on providing top-tier patient experience. He also shares important lessons he learned along the way about financial planning, a profit-first mindset, and more. Per usual, I'm confident you'll get more than a few tidbits from this interview that, if put to use, will shape your practice for the better. If you're ready to implement more efficient & effective marketing strategies for your practice, book your FREE strategy session & marketing plan: https://go.medspamagicmarketing.com/schedule About Dr. Brandon Kirsch - Kirsch Dermatology & Med Spa Dr. Brandon Kirsch's work spans the worlds of dermatology, technology, business and law. He is a board-certified dermatologist who started his career as a lawyer and holds law degrees from the University of Western Ontario (LL.B.) and Georgetown University (LL.M. Securities and Financial Regulation). He completed medical school at Brown University, an internship at the Mayo Clinic and dermatology residency at the University of North Carolina. Dr. Kirsch serves as Chief of Dermatology for Naples Community Hospital. He has previously worked as Assistant Clinical Professor of Dermatology at the University of Colorado, Vice President and Therapeutic Area Head of Dermatology at the global biopharmaceutical company Arena Pharmaceuticals, and Vice President and Medical Director at Brickell Biotech, Inc. In his roles at Arena and Brickell, he was responsible for providing leadership and strategic direction to the clinical science team and overseeing research studies. Dr. Kirsch has also provided strategic medical consulting for the clinical-stage biopharmaceutical company Dermavant Sciences, Inc. Dr. Kirsch is a frequent contributor to the HuffPost and has been published in the Journal of the American Medical Association, Journal of the American Academy of Dermatology, Journal of Drugs in Dermatology, Journal of Clinical and Aesthetic Dermatology, Dermatology Times, The Journal of Investigative Dermatology, The Journal of Cancer Immunology Research, The Canadian Journal of Neurological Sciences, Reason, The Wall Street Journal, The Toronto Star, The Providence Journal, and The Jacksonville Times-Union. Read more about Dr. Kirsch's story here: https://www.kirschderm.com/dr-brandon-kirsch/ Read more about Kirsch Dermatology here: https://www.kirschderm.com/why-choose-us/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerErin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.Co-Chair/PlannerDavid Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerErin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.Co-Chair/PlannerDavid Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Natürlich ist der eigentlich große, fette Aufreger der Woche, dass es die Ratingagentur Fitch tatsächlich gewagt hat, die Supermacht USA wegen der präkären Haushaltslage von „Triple A“ auf „AA+“ herabzustufen und damit die Aktienmärkte weltweit auf Talfahrt zu schicken. Mit dem unvermeidbaren, längst überfälligen Schelte für die USA befasste sich allerdings schon die gestrige Börsenminute und es wird erneut ein Thema in der neuen Podcastfolge der GELDMEISTERIN am Sonntag mit Thomas Mayer sein, Ökonom und Gründer des Research Institutes der Fondsgesellschaft Flossbach von Storch. Was diese Woche noch aufregte, obwohl ihm nachgesagt wird, das es beruhigt ist Cannabis. Es klang verlockend: Juicy Fields, ein Cannabis-Growdgrowing-Projekt in der Steiermark. Tatsächlich ist das vermeintlich lukrative Investment, so warnt die österreichische Wirtschafts- und Korruptionsanwaltschaft, nur Rauch und Schall und soll Anlegergelder von rund 400 Millionen Euro verbrannt haben. Ein ähnlich Anlagebetrugs-Verdachtfall, „My first plant“ wird in Kärnten nachgegangen. Hier besteht auch noch der Verdacht der Geldwäsche. Betroffen sind nicht nur tausende geblendete Investoren in Österreich, sondern weltweit. Ihnen wurden auf wohlgestalteten Internetseiten ertragreiche Investments in den Anbau und Verkauf von medizinischen Cannabis- und CBD-Produkten versprochen. Es besteht der Verdacht, dass ein Großteil der Gelder nie investiert wurde, wobei natürlich für alle Beteiligten die Unschuldsvermutung gilt. Mein alter Freund, Promi-Investor Jim Rogers, erzählt im Podcast GELDMEISTERIN im Vorjahr, dass er auch in einer Cannabis-Plantage für medizinische Produkte direkt in Kolumbien investiert sei. Versteht mich nicht falsch, daran ist nichts Anrüchiges. Nur ich würde es nicht tun. Und das gar nicht einmal, weil ich keine Freundin von Cannabis für den nichtmedizinischen Gebrauch bin, sondern weil mir die Cannabis-Aktien einfach zu heiß sind. Alleine deshalb schon, weil sie vom staatlichen Goodwill der Legalisierung abhängen. Wenn, dann würde ich mich wirklich nur an die großen Player investieren wie die Cronos Group mit einer Marktkapitalisierung von knapp 600 Millionen Euro, in die 2019 auch der US-Tabakkonzern Altria einstieg, oder in die kanadischen Platzhirschen wie Tilray (rund 870 Millionen Euro Marktkapitalisierung), Canopy Growth (Börsenwert über 270 Millionen Euro) oder die populäre Aurora Cannabis-Aktie (181 Millionen Euro Marktkapitalisierung). Es werden auch Cannabis-Aktien-Index gehandelt und es gibt mit Cannabis-Reit eigene Cannabis-Immobilienakten. Solche Spezialindizes und -Fonds bergen für mich zu viel Klumpenrisiko. Da würde ich mich persönlich schon mit einer Pfizer-Aktie, die mit Arena Pharmaceuticals auch einen medizinischen Cannabis-Produzenten in ihrer Gruppe an, wohler und breiter aufgestellt fühlen. Aber wie gesagt, für mich muss es kein Cannabis-Investment sein, da gibt es noch so viel anderen spannende Sektoren, zu denen aktuell offensichtlich nicht die Immobilien zählen. Mehr dazu in der aktuellen Podcast-Folge der Geldmeisterin am kommenden Sonntag. Ich hoffe wir hören uns. Ein schönes Wochenende wünscht Julia Kistner Rechtshinweis: Dies ist die Meinunung der Autorin und keine Anlageempfehlung. Was ihr daraus macht ist Eure Sache, Julia Kistner übernimmt hierfür keine Haftung. #investieren #Cannabis #Anlagebetrug #podcast Foto: Unsplash/Desighecologist

Almost half of American voters would give serious thought to casting a ballot for a third-party candidate if President Biden and former President Donald Trump are the Democratic and Republican nominees next year, according to a new poll. Roughly 20% of those polled said they would vote for socialist Bernie Sanders. Is there actually a viable third party, or would this just guarantee the outcome one way or the other? Pfizer recently completed its acquisition of Arena Pharmaceuticals, adding a portfolio with “diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology.” Essentially, Pfizer acquired a company that makes drugs that treat the side effects of the jabby-jab. Speaking of side effects of the jab, Peter McCullough recently spoke on a podcast about Jamie Foxx and his recent health struggles. According to McCullough, Foxx indeed suffered a severe stroke that's left him blind and paralyzed. Why is the corporate press not covering this? Is Hollywood covering up the situation for Big Pharma? Something is going on, and hopefully we'll find out what that is soon. Harry Sisson and Chris Mowrey, everyone's favorite Gen Z activists, are back with another cringey video touting Joe Biden as being fit and extremely productive. Obviously, that's entirely untrue, but one has to respect their commitment to the hustle. Discovery advertised a new show about Abraham Lincoln that claims Lincoln was actually gay. Only three more weeks left of Pride Month! Today's Sponsors: Birch Gold As BRICS… Brazil, Russia, India, China and South Africa… band together against the dollar, more and more Central Banks are diversifying…you know what they're buying? GOLD! Follow their lead. Text CHAD to 989898 for your free infokit on gold. There's no obligation, just information. With an A+ rating with the Better Business Bureau and THOUSANDS of happy customers, Birch Gold can help protect your savings too. Patriot Mobile When you switch to Patriot Mobile, you're sending a message that you support free speech, religious freedom, the sanctity of life, Second Amendment, and our military, veterans and first responder heroes! Get FREE ACTIVATION today with the offer code CHAD. Ask about their coverage guarantee while you're there… Get the same dependable service and take a stand for your values, make the switch today! Visit https://www.PATRIOTMOBILE.COM/CHAD or call 878-PATRIOT. Barrel Buddy Cleaning our guns is a REALLY important step in being a responsible gun owner. Barrel Buddy is a totally new concept and better way to take care of your firearms. So, get some today … I guarantee you'll love ‘em. Go to BarrelBuddy.com today! Jase Medical THE JASE CASE FROM JASE MEDICAL IS A GREAT WAY TO KEEP YOURSELF PREPARED FOR THE WORST. IT'S A PACK OF 5 DIFFERENT COURSES OF ANTIBIOTICS THAT YOU CAN USE TO TREAT A LONG LIST OF BACTERIAL ILLNESSES – THINGS LIKE UTIs, RESPIRATORY INFECTIONS, SINUSITIS, SKIN INFECTIONS, AND A LOT MORE. LISTEN: DON'T GET CAUGHT UNPREPARED. GO TO https://www.JASEMEDICAL.COM AND ENTER CODE “CHAD” AT CHECKOUT. Learn more about your ad choices. Visit megaphone.fm/adchoices

Some people say that biotechnology is similar to speculative oil drilling for PhDs. We are joined today by Amit Munshi, a serial entrepreneur and a turnaround expert with over 30 years of remarkable experience in biotech. From founding Kythera Biopharmaceuticals (sold to Allergan for $2.1 billion) to leading a successful turnaround at Arena Pharmaceuticals (sold to Pfizer for $6.7 billion), Amit truly knows what it takes to be a successful entrepreneur in this industry. In today's episode, he shares his insights on taking risks, finding the right capital structure for your company, and the ultimate goal of bringing life-saving drugs to market. So, grab your headphones and TUNE IN to Amit's magical journey through life.For detailed transcript and show notes, please visit TheFounderSpirit.com. Also follow us on: LinkedIn: https://www.linkedin.com/company/the-founder-spirit-podcastInstagram: https://www.instagram.com/thefounderspirit_podcastYouTube: https://www.youtube.com/@TheFounderSpiritPodcast Facebook: https://www.facebook.com/TheFounderSpirit Twitter: https://twitter.com/founder_spirit This episode is brought to you by NIANCE, Deeper than Beauty. NIANCE is a science-based Swiss luxury skincare and nutritional supplement brand focused on activating the body's natural ability to rejuvenate and regenerate for a more vital, useful, and energetic appearance. Powered by groundbreaking furnace biotechnology, its award-winning formulas, with the exclusive Swiss Glacier complex, combine over a hundred powerful natural active ingredients with leading clinical research. As listeners of my podcast, you can benefit from 15% discount by using the promo code “TheFounderSpirit15” on niance.com.About This Podcast:Whether you are an entrepreneur, a mid-career professional or someone who's just starting out in life, The Founder Spirit podcast is for you!In this podcast series, we'll be interviewing exceptional individuals from all over the world with the founder spirit, ranging from social entrepreneurs, tech founders, to philanthropists, elite athletes, and more. Together, we'll uncover not only how they manage to succeed in face of multiple challenges, but also who they are as people and their human story.So TUNE IN & be inspired by stories from their life journey!

ESG Stock Picks for January 2023. Articles include: “Jim Cramer recommends these 5 health care stocks in 2023”; “Goldman Sachs Says Investors Should Buy These 3 Solar Energy Stocks; Sees Over 50% Upside Potential”; “12 Best Solar Energy Stocks to Invest In Heading into 2023”; “8 Best Wind Power Stocks Of 2023”; and many more Transcript & Links, Episode 97, January 13, 2023 Hello, Ron Robins here. Though a little late, I sincerely wish you a terrific, happy, healthy, and prosperous New Year! So, welcome to my first podcast of 2023 episode 97 and published on January 13, 2023, titled “ESG Stock Picks for January 2023” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief so that I can get as many companies covered as possible in the time allowed. Please go to this podcast's webpage for links to the actual articles for more company and stock information. Also, several companies are covered more than once and there are also 12 article links below that time didn't allow me to review here. ------------------------------------------------------------- 1) ESG Stock Picks for January 2023 So, let's start with Jim Cramer recommends these 5 health care stocks in 2023, by Krystal Hur on cnbc.com. These are the five stocks with brief comments by Krystal Hur. “Danaher. Cramer predicted that the company will have a banner year in 2023 and called it ‘one of the best-run companies in any industry.' Pfizer. Praising the vaccine maker's acquisition of Arena Pharmaceuticals, Biohaven and Global Blood Therapeutics, he said that Pfizer stock is a steal. UnitedHealth Group. Cramer said that he likes the ‘best-of-breed' managed health care stock. Humana. He called the stock a ‘great turnaround story.' Edwards Lifesciences. Cramer says he likes the stock because the company's underlying business has been strong, despite the stock being down over 43% for the year.  Disclaimer; Cramer's Charitable Trust owns shares of Danaher and Humana.” End quotes. ------------------------------------------------------------- 2) ESG Stock Picks for January 2023 Now back to familiar territory with this article titled Goldman Sachs Says Investors Should Buy These 3 Solar Energy Stocks; Sees Over 50% Upside Potential. It's by TipRanks and found on yahoo.com. Here are some quotes from the story. “Banking giant Goldman Sachs believes the Inflation Reduction Act… clears the way for at least a decade-long runway for stable installation growth across all residential, commercial and utility-scale markets… We've used the TipRanks database to pull up three solar power recommendations by Goldman's 5-star analyst Brian Lee. Lee has tapped these stocks as buying propositions, and sees them bringing 50% upside – or better… 1. Enphase Energy, Inc. (ENPH) Inverters, Enphase's chief product line, convert the DC power to usable alternating current (AC) power suitable for residential and commercial distribution… Overall, there are 17 recent analyst reviews available on Enphase shares, and these include 14 Buys and 3 Holds for a Strong Buy consensus rating. (See Enphase stock forecast on TipRanks). 2. First Solar, Inc. (FSLR) … has been in business since 1999 and is the largest US-based maker of photovoltaic (PV) panels, focuses on cutting-edge PV technology, from the manufacture of thin-film PV modules at commercial scale to the maintenance and recycling of spent panels… Wall Street takes a bullish stance on First Solar. 12 Buys and 5 Holds issued over the previous three months make the stock a ‘Moderate Buy.' (See FSLR stock forecast on TipRanks). 3. Array Technologies, Inc. (ARRY) … has built its niche around solar tracker technology, needed to keep photovoltaic panels properly oriented to the sun for maximum power production… Overall, the 9 recent analyst reviews on ARRY add up to a Moderate Buy consensus rating, with 7 Buys, 1 Hold, and 1 Sell. (See Array stock forecast on TipRanks).” End quotes. ------------------------------------------------------------- 3) ESG Stock Picks for January 2023 Continuing on the solar theme is this article titled 12 Best Solar Energy Stocks to Invest In Heading into 2023. It's by Mohammed Saqib, on Insider Monkey, and found on yahoo.com. Now some quotes on each stock by Mr. Saqib. “We started with the holdings of Global X Solar ETF (RAYS) and ranked its holdings using Insider Monkey's proprietary hedge fund sentiment data which tracks the holdings of over 900 elite hedge funds. 12. Daqo New Energy Corp. (NYSE:DQ) Number of Hedge Fund Holders: 20 Headquartered in Shanghai, Daqo New Energy is a global leader in the production of high-purity polysilicon for the solar PV sector… On December 5, 2022, Chao Ji, an analyst at Goldman Sachs, reduced her price target on Daqo New Energy to $70 while keeping a Neutral rating on the stock. 11. Atlantica Sustainable Infrastructure plc (NASDAQ:AY) Hedge Fund Holders: 21 Atlantica Sustainable Infrastructure is a United Kingdom-based sustainable infrastructure company that owns, operates, and invests in renewable energy, storage, efficient natural gas and heat, transmission lines, and water assets across North America, South America, and Europe. 10. Shoals Technologies Group, Inc. (NASDAQ:SHLS) Hedge Fund Holders: 21 The company sells EV Charging solutions in the United States for public and fleet electric car charging stations…. On November 16, 2022, Christine Cho, an analyst at Barclays… (said) the company is still in a strong position with improved backlog visibility and a more enticing value proposition. 9. Canadian Solar Inc. (NASDAQ:CSIQ) Hedge Fund Holders: 22 Canadian Solar is one (of the) world's largest solar technology and renewable energy firms. The company is a major solar photovoltaic module producer and a manufacturer of battery storage projects with a diverse geographical pipeline at various stages of development. 8. Sunnova Energy International Inc. (NYSE:NOVA) Hedge Fund Holders: 25 Sunnova Energy International provides home solar and energy storage services… Sunnova Energy has roughly 195,000 subscribers… On December 13, 2022, Biju Perincheril, an analyst at Susquehanna, reiterated his Positive rating on Sunnova Energy International. 7. SunPower Corporation (NASDAQ:SPWR) Hedge Fund Holders: 26 SunPower Corporation is a leading provider of solar technology and energy services that provides fully integrated solar, storage, and home energy solutions to consumers, mainly in the United States and Canada, through a variety of hardware, software and financing options, as well as Smart Energy solutions. 6. Array Technologies, Inc. (NASDAQ:ARRY) Hedge Fund Holders: 29 Array Technologies is a global utility-scale solar tracker technology… On December 6, 2022, Michael Blum, an analyst at Wells Fargo, started covering Array Technologies… with… an Overweight rating on the stock. 5. Altus Power, Inc. (NYSE:AMPS) Hedge Fund Holders: 33 Altus Power is a clean energy electrification company headquartered in Connecticut, USA. The company creates and operates photovoltaic solar energy storage systems… On December 13, 2022, Ryan Levine, an analyst at Citi, reduced his price target on Altus Power to $10 while keeping a Buy rating on the stock… 4. SolarEdge Technologies, Inc. (NASDAQ:SEDG) Hedge Fund Holders: 44 SolarEdge Technologies is an Israeli company that designs and distributes photovoltaic inverters, energy generation monitoring software, and battery energy storage devices… On December 14, 2022, Christine Cho, an analyst at Barclays, raised her price target on SolarEdge Technologies to $396 and upgraded the stock's rating to Overweight. 3. First Solar, Inc. (NASDAQ:FSLR) Hedge Fund Holders: 45 First Solar is a global PV solar energy solutions provider and a major American solar technology company… First Solar… is the world's largest producer of thin-film PV solar modules.­ On November 14, 2022, Corinne Blanchard, an analyst at Deutsche Bank, started covering First Solar with a price target of $180 and a Buy rating on the stock. 2. Sunrun Inc. (NASDAQ:RUN) Hedge Fund Holders: 47 Sunrun Inc. is a company that designs and develops home solar energy systems in the United States. Furthermore, the company provides battery storage systems… On November 11, 2022, Elvira Scotto, an analyst at RBC Capital, reduced her price target on Sunrun to $42 while keeping an Outperform rating on the stock. 1. Enphase Energy, Inc. (NASDAQ:ENPH) Hedge Fund Holders: 59 The company develops and manufactures microinverters, solar panels, and energy storage systems for the residential and commercial markets. Enphase Energy, Inc… operates in more than 21 countries worldwide. On October 26, 2022, Biju Perincheril, an analyst at Susquehanna, increased his price target on Enphase Energy, Inc. to $310 from $290 while keeping a Positive rating on the stock.” End quotes. ------------------------------------------------------------- 4) ESG Stock Picks for January 2023 From solar, now to wind power with this article titled 8 Best Wind Power Stocks Of 2023, by Cory Mitchell on forbes.com. Due to the structure of the article, I'm going to just list the company names here. Dominion Energy, Inc. (D) Northland Power (NPI.CA) Eversource Energy (ES) Iberdrola S.A. (IBDRY) Brookfield Renewable Partners L.P. (BEP) Vestas Wind Systems (VWDRY) Boralex Inc. (BLX.CA) Orsted A/S (DNNGY) ------------------------------------------------------------- 5) ESG Stock Picks for January 2023 Next is this article America's Most Responsible Companies 2023 by Newsweek and Statista, found on newsweek.com. Some quotes… “Newsweek has partnered with global research and data firm Statista for our fourth annual list of America's Most Responsible Companies. This year our list includes 500 of the U.S's largest public corporations.” End quotes. The top five companies are HP (HP), General Mills (GIS), Whirlpool Corporation (WHR), Merck & Co (MRK), and Clorox (CLX). ------------------------------------------------------------- 6) ESG Stock Picks for January 2023 Now many ethical and sustainable investors -- particularly if they're looking for income -- will seek ethical dividend-paying stocks. Thus, this article is for them! It's titled 16 Ethical Dividend Stocks to Invest in Today and is by the Impact Investor on theimpactinvestor.com. Here're some quotes from the article. “I pride myself on being an ethical investor…. I sometimes choose ESG stocks… However, I also make investment decisions independent of ESG rankings based on my ethics. I particularly value companies that provide opportunities for advancement to all their people and help equalize access to the world's resources. Protecting the environment also is significant for me. I also avoid ‘sin' stocks… Of course, I expect a dividend yield from my stocks.” End quotes. Among the dividend-paying stocks The Impact Investor recommends are: Nestle SA (NSRGY), Proctor & Gamble (PG), 3M (MMM), The Clorox Company (CLX), and Becton, Dickinson and Company (BDX). ------------------------------------------------------------- Now some Other Honorable Mentions – no particular order 1. Title: 10 Best-Performing Technology ETFs in 2022 on yahoo.com. By Omer Farooq. 2. Title: 7 Best Socially Responsible Funds on Investing usnews.com. By Jeff Reeves. 3. Title: Brookfield Infrastructure: It's Not Been This Cheap In A Long Time (NYSE:BIP) on seekingalpha.com. By Jonathan Weber. 4. Title: 10 Cheap Solar Stocks to Buy on yahoo.com. By Affan Mir. 5. Title: AvalonBay Communities a Top Socially Responsible Dividend Stock With 3.9% Yield (AVB) on nasdaq.com. By BNK Invest. 6. Title: Got $5,000? 3 Top Infrastructure Stocks to Buy for the Long Term on fool.com. By Reuben Gregg Brewer. 7. Title: 3 Tech Titans Worth Owning in 2023 (and Beyond) on fool.com. By Justin Pope, Will Healy, and Jake Lerch. 8. Title: The Best Energy Dividend Stock for a Decade of Passive Income on fool.com. By Matt DiLallo. Articles From Outside the US 1. Australia: Some upside surprises, and 8 ethical stocks to watch - livewiremarkets.com. By Australian Ethical. 2. Australia: ASX shares: Six sustainability ETFs worth watching on afr.com. By Tony Featherstone. 3. India: Top 10 companies in India for CSR and Sustainability in 2022 on thecsrjournal.in. By the CSR Journal. 4. Canada: 2023 Responsible Funds Guide by Corporate Knights on corporateknights.com. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “ESG Stock Picks for January 2023.” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these terribly troubled times! Contact me if you have any questions. Thank you for listening. Again, wishing you and your family and friends a great 2023! Talk to you next January 27th. Bye for now. © 2023 Ron Robins, Investing for the Soul  

On this week's episode editors Virginia Li and Simon King discuss FDA approval of the first novel checkpoint inhibitor for eight years – Bristol Myers Squibb's LAG-3 inhibitor relatlimab – and evaluate positive data for Pfizer's etrasimod, which it gained via December's $6.7 billion acquisition of Arena Pharmaceuticals. In addition, FirstWord's Michael Flanagan speaks to Adam Brufsky – professor of medicine at the University of Pittsburgh School of Medicine and associate chief for the school's haematology/oncology division – to discuss the relevance of recent clinical and regulatory events that will impact the treatment of breast cancer.

Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president and CEO of Aristea, about the decision to form the company, its lead therapy in development, and its collaboration and development deal with Arena Pharmaceuticals that gives its partner an option to acquire it outright.

Pharmaceutical giant Pfizer looks poised to enter the medicinal cannabis arena with a US$6.7 billion agreement to purchase Arena Pharmaceuticals, a biotech company with a pipeline dedicated to cannabinoid-type therapeutics. In New Zealand, we seem to be lagging in exploring the possibilities of the medicinal cannabis market.

Pfizer entered the medical cannabis industry betting on a promising cannabinoid-based bowel disease treatment, signing an agreement with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion in an all-cash transaction.The interest of cannabis' many benefits from the global pharmaceutical industry, known as #BigPharma, will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies."The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options." Pharmaceutical companies will lean on drugs that contain synthetic versions of CBD and THC, while continuing to acquire patents to secure the rights to various CBD extraction methods and concoctions designed to treat a myriad of ailments.Episode 865 The #TalkingHedge dives into Forbes' article...https://youtu.be/IpnZxGiOLOA

The pharmaceutical giant Pfizer has announced plans to purchase Arena Pharmaceuticals, Inc., The acquisition includes Arena's investigational drug Olorinab, an oral, full agonist of the CB2 receptor formulated to treat symptoms associated with gastrointestinal disorders and other drugs that treat immune-inflammatory diseases. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss whether a spate of deals this week is evidence of an eventful year ahead for bio-pharma M&A, take a closer look at Pfizer's acquisition of Arena Pharmaceuticals and highlight some of the standout moments from the recent ASH conference.

THE SCRIPTURE:  1 Timothy 6:17-19 New International Version 17 Command those who are rich in this present world not to be arrogant nor to put their hope in wealth, which is so uncertain, but to put their hope in God, who richly provides us with everything for our enjoyment. 18 Command them to do good, to be rich in good deeds, and to be generous and willing to share. 19 In this way they will lay up treasure for themselves as a firm foundation for the coming age, so that they may take hold of the life that is truly life. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults BREAKING: Pfizer to acquire Arena Pharmaceuticals, a company that specializes in treatments for cardiovascular issues and autoimmune disorders Tony Fauci is now going to pretend he warned everyone about the injections not stopping transmission.   See omnystudio.com/listener for privacy information.

US stocks fell Monday. Plus, Pfizer is buying Arena Pharmaceuticals for $6.7 billion, Rivian notches MotorTrend's truck of the year, and the Fed begins its two-day meeting.

Pfizer expands its cancer and inflammatory disease drug pipeline with a new acquisition. Electric vehicle brand LiveWire is going public via SPAC. And Delta positions itself for growth in 2022. Host: Shaina Mishkin. Producer: Katie Ferguson. Learn more about your ad choices. Visit megaphone.fm/adchoices

US stocks fell Monday. Plus, Pfizer is buying Arena Pharmaceuticals for $6.7 billion, Rivian notches MotorTrend's truck of the year, and the Fed begins its two-day meeting.

My guest today is Steven Stein, Sr. Director, Global Field Medical Head, Arena Pharmaceuticals, and we discuss how and why MSL's bring value to an organization.   Steven shares…  

Midas ile Piyasa Turu başlıyor! 14 Aralık Salı günkü bölümümüzde; yükseliş ve düşüş yaşayan hisseler, Avustralya'da aşı üretmeye başlayacak olan Moderna, bir kez daha hisselerini satan Elon Musk ve gündeme dair diğer haberler var. Podcastimizin detaylı akışı ise şu şekilde: (0.51) / Yükseliş ve düşüş yaşayan hisseler ve bu hareketlenmenin nedenleri (2.30) / Moderna, Avustralya'da milyonlarca mRNA aşısı üretecek (2.58) / Harley-Davidson'ın LiveWire'ı halka arz olmaya hazırlanıyor (3.26) / İngiltere gözlemcisi, Microsoft'un satın alımını inceliyor (3.54) / Elon Musk, bir kez daha Tesla hissesi sattı (4.22) / Pfizer, Arena Pharmaceuticals'ı satın alıyor (4.52) / “Meta”, eski adıyla “Facebook”a oldukça pahalıya mal oldu. (5.21) / Gündeme dair diğer haber başlıkları Piyasa Turu'nda bahsi geçen haberleri okumak isterseniz, getmidas.com/midasin-kulaklari adresindeki Piyasa Öncesi bültenimize ve diğer haberlerimize göz atabilirsiniz. Midas'ın Kulakları: https://www.getmidas.com/midasin-kulaklari Twitter: https://twitter.com/getmidas Instagram: https://www.instagram.com/get_midas/

Vaccine makers surge on signs of demand for Covid-19 boosters. Pfizer to acquire Arena Pharmaceuticals for $6.7 billion. Harley-Davidson's electric-vehicle division to go public via SPAC. GameStop, AMC shares fall in blow to meme-stock investors. Brent crude futures decline 1%. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

The ASX is set to follow US sharemarkets lower after stocks tumbled on Monday as traders weighed the potential impacts of less generous monetary policy settings amid Omicron Covid-19 challenges and lofty equity valuations. Shares of Tesla were down 5% with Apple (-2.1%) shares whipsawing as it approached a US$3 trillion market value. Travel companies Carnival (-4.9%) and United Airlines (-5.2%) sold-off. But Pfizer shares rose 4.6% as it agreed to acquire Arena Pharmaceuticals (+80.4%) for US$6.7 billion. Moderna's shares lifted 5.8% on a White House push for Covid-19 booster shots. At the close of trade, the Dow Jones index fell by 320 points or 0.9% after being down by 361 points earlier in the session. The S&P 500 index dipped by 0.9%, down from a record, with the Nasdaq index lower by 217 points or 1.4%. This report is approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814 (CommSec) a wholly owned but non-guaranteed subsidiary of the Commonwealth Bank of Australia ABN 48 123 123 124 AFSL 234945 (the Bank), and a market participant of ASX Limited and CHI-X Pty Limited, a clearing participant of ASX Clear Pty Limited and a settlement participant of ASX Settlement Pty Limited. Any advice contained in this report is general advice only and is not a recommendation to buy, sell or hold any securities, property, real estate or financial products, and has been prepared without taking account of the objectives, financial or taxation situation or needs of any particular individual. Before making any investment decision, you should consider your own investment needs and objectives and consider seeking financial advice. Past performance is not a reliable indicator of future performance. This report is produced by Commonwealth Securities Limited based on information available at the time of publishing.  We believe that the information in this report is correct and any opinions, conclusions or recommendations are reasonably held or made as at the time of its compilation, but no warranty is made as to accuracy, reliability or completeness.  To the extent permitted by law, neither the Bank nor any of its subsidiaries accept liability to any person for loss or damage arising from the use of this report. 

The Filtrate:Joel TopfSwapnil HiremathNayan AroraJennie LinJoshua WaitzmanSpecial GuestsAlfred Kim assistant Professor at Washington University, director of the lupus clinic. Receives support from Arena Pharmaceuticals, manufacturer of volcloosporin, or at least he did before this episode aired.Dawn Castor assistant professor at The University of Louisville School of Medicine. She is on the speaker bureau for Arena Pharmaceuticals, manufacturer of volcloosporin. She was a site principle investigator (PI) as well as an author of the trial.EditorNayan AroraShow Notes:NIH Cyclophosphamide trial, long term follow-up: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Other important publications on this trial include:Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs NEJM 1986Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 1992Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamideVoclosporin is approved by FDA in January 2021Previous Lupus Nephritis podcast with Dawn and Alfred: Freely Filtered 029: Belimumab for lupus nephritisRituximab în Lupus. The LUNAR Trial (Spoiler, it didn't work): Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studySystematic review of the literature on reproducibility of the interpretation of renal biopsy in lupus nephritisConclusion The interpretation of renal biopsy in lupus nephritis is poorly reproducible, causing serious doubts about its validity and its clinical application. As it can lead to serious diagnosis, treatment and prognosis errors, it is necessary to intensify research in this field.The ALMS trials of mycohenolate mofetil (MMF) trials in lupus nephritisInduction: Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis (JASN 2009)Maintenance: Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis (NEJM 2011)Jacob deGrom on the mound. Baseball Reference. DeGrom is a two time Cy Young award winner, a 4-time All-Star and former Rookie of the Year winner.AURORA2: Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (ClinicalTrials.gov)Aurinia Pharmaceuticals.KDIGO 2021 Glomerulonephritis Guidelines Daily aspirin vs placebo for suspected acute myocardial infarction is highly protective except for patients born under Libra or Gemini. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient careMultitarget therapy for induction treatment of lupus nephritis: a randomized trial.Patient Benefits Justify Price of New Lupus Nephritis Drugs“The estimated annual price of belimumab is approximately $43,000 per patient; the estimated annual price for voclosporin is approximately $92,000 per patient.”2019 update of the EULAR recommendations for the management of systemic lupus erythematosus GuidelineDr. Glaucomflecken on TwitterCardiology vs Nephrology Round 1Nephrology vs Cardiology Round 2In the Heights (Wikipedia)The Mitchells vs. the Machines (Wikipedia)Paws in PrisonFlozinator pin

Sormeh Mahjouri, MPH, PMP, Senior Manager, Study Recruitment Optimization at Arena Pharmaceuticals, Inc. is interviewed in this episode. Follow Adam on Instagram at Ask Adam Torres for up to date information on book releases and tour schedule. Apply to become a featured co-author in one of Adam's upcoming books: https://www.moneymatterstoptips.com/coauthor --- Support this podcast: https://anchor.fm/moneymatters/support

Up until about three years ago Kevin Lind would likely have been identified as yet another gifted private equity executive – capable of issuing business remedies from the tip of his tongue. At least in the minds of his CFO peers, who are accustomed to listening to PE pundits routinely hand down such remedies for ailing businesses. For Lind the CFO office at Arena Pharmaceuticals is a game changer, where he no longer hands down remedies but serves as a finance leader – an individual tasked with summoning others forward and building trust across an organization even as he or she sometimes completes necessary layoffs. “Good drugs can succeed in spite of bad management and bad management can fail despite good drugs,” explains Lind, who says the frequent mismatch led him to want to get “one step closer” to management decision making.  Lind would take that one step after receiving a call from Amit Munshi, CEO of Arena Pharmaceuticals. At first, Lind was less than interested. Arena’s past struggles were not unknown to him – but Munshi encouraged Lind to take a close look at the company’s pipeline.  “From an investment point of view the pipeline was really interesting and there was a turnaround opportunity if we got the right management team together,” recalls Lind, who said knowing Arena was a turnaround – and not a standard CFO tour of duty – made it far more appealing.  – Jack Sweeney

Preston Klassen, MD Chief Medical Officer, Arena Pharmaceuticals talks about the challenges of treating Inflammatory Bowel Diseases (IBD) and Arena's developmental therapies for ulcerative colitis and Crohn's disease.  We also talk about the development of a treatment for related gastrointestinal pain with a non-opioid alternative. #Arena  #Ulcerativecolitis #GI  #IBD  #crohns @ArenaPharm  Arena Pharmaceuticals     Arena Pharmaceuticals

Today in FirstWord:

On this week's Tech Nation, Moira speaks with … Stanford History professor Tom Mullaney about “The Chinese Typewriter”. And on Tech Nation Health, we celebrate the Summer of Love. Chief Correspondent Dr. Daniel Kraft follows the recreational drugs through today with new therapeutics. And Amit Munshi, the President & CEO of Arena Pharmaceuticals tells us about their many drug candidates, including one sourced from cannabinoids.

On Tech Nation Health, we celebrate the Summer of Love. Chief Correspondent Dr. Daniel Kraft follows the recreational drugs through today with new therapeutics. And Amit Munshi, the President & CEO of Arena Pharmaceuticals tells us about their many drug candidates, including one sourced from cannabinoids.

On this week’s Tech Nation, Moira speaks with … Stanford History professor Tom Mullaney about “The Chinese Typewriter”. And on Tech Nation Health, we celebrate the Summer of Love. Chief Correspondent Dr. Daniel Kraft follows the recreational drugs through today with new therapeutics. And Amit Munshi, the President & CEO of Arena Pharmaceuticals tells us about their many drug candidates, including one sourced from cannabinoids.

Today in FirstWord:

On Tech Nation Health, we celebrate the Summer of Love. Chief Correspondent Dr. Daniel Kraft follows the recreational drugs through today with new therapeutics. And Amit Munshi, the President & CEO of Arena Pharmaceuticals tells us about their many drug candidates, including one sourced from cannabinoids.

Today in FirstWord:

Today in FirstWord: